Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE™FL-2: Epcoritamab + R2 vs Chemoimmunotherapy in Untreated Follicular Lymphoma
NCT06191744Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Feb 2024
- Primary completion
- Nov 2037
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 32
01
Overview
A Phase 3 trial of epcoritamab in follicular lymphoma (FL), sponsored by Genmab. Started Feb 2024; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06191744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191744.